




Correction to: SEOM clinical guideline for treatment of kidney cancer (2017)

E. Gallardo¹ · M. J. Méndez-Vidal² · J. L. Pérez-Gracia³ · J. M. Sepúlveda-Sánchez⁴ · M. Campayo⁵ · I. Chirivella-González⁶ · X. García-del-Muro⁷ · A. González-del-Alba⁸ · E. Grande⁹ · C. Suárez¹⁰ 

Published online: 23 February 2019
© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Correction to: Clin Transl Oncol (2018) 20:47–56
<https://doi.org/10.1007/s12094-017-1765-4>

The conflict of interest declaration was published incorrectly in the original version. The correct conflict of interest declaration should read as follows: E. Gallardo has served as a consultant or Advisory Role to Pfizer, Bayer, Roche, Ipsen, Novartis, EUSA Pharma, BMS; serve as speaker to Bayer, Ipsen, Pfizer, Roche, BMS, Novartis; has received a Grant support from Bayer, Ipsen; has received Travel grants from

Bayer, Ipsen, Roche, Novartis, Pfizer, GSK. M. J. Méndez-Vidal has received honoraria and/or travel support from Janseen-Cilag, Bayer, Sanofi Aventis, Astellas Medivation, Roche, Bristol-Myers Squibb, Novartis, Pfizer, EISAI and Ipsen. J. L. Pérez-Gracia has served as a consultant to Bristol-Myers Squibb and Roche; has received research and travel grants and lecture fees from Bristol-Myers Squibb and Roche. Has received research and travel grants from MSD. J. M. Sepúlveda-Sánchez has no conflict of interest to declare. M. Campayo has received honorariums and

The original article can be found online at <https://doi.org/10.1007/s12094-017-1765-4>.

✉ C. Suárez
csuarez@vhio.net

E. Gallardo
egallardo@tauli.cat

M. J. Méndez-Vidal
mjosemv@yahoo.es

J. L. Pérez-Gracia
jlgracia@unav.es

J. M. Sepúlveda-Sánchez
jmsepulveda.hdoc@salud.madrid.org

M. Campayo
mcampayo@mutuaterrassa.es

I. Chirivella-González
chirivella_isa@gva.es

X. García-del-Muro
garciadelmuro@iconcologia.net

A. González-del-Alba
aranzazu.gonzalezdelalba@ssib.es

E. Grande
egrande@oncologiahrc.com

² Medical Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Córdoba, Spain

³ Medical Oncology Department, Clínica Universidad de Navarra, Pamplona, Spain

⁴ Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain

⁵ Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Spain

⁶ Medical Oncology Department, Hospital Clínico, Universidad de Valencia, Valencia, Spain

⁷ Medical Oncology Department, Institut Català d'Oncologia, Idibell, Universitat de Barcelona, Barcelona, L'Hospitalet de Llobregat, Spain

⁸ Oncology Department, Hospital Universitario Son Espases, Palma De Mallorca, Spain

⁹ Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain

¹⁰ Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain

¹ Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Parc Taulí, 1, 08208 Sabadell, Spain

travels grants from Pfizer, Novartis, Bristol-Myers Squibb and Bayer; has served as advisory role to Pfizer, and Bayer. I. Chirivella-González has received research fundings or consulting honoraria from Amgen, Astellas, AstraZeneca, Bayer, Bristol, Janssen, Novartis, Pfizer, Roche and Sanofi. X. García-del-Muro has served as consultant or advisory board to Pfizer, Bristol-Myers Squibb, Ipsen, Roche, Lilly, PharmaMar, EusaPharma; has served as speaker to Pfizer, Bristol-Myers Squibb, Ipsen and PharmaMar; has received research grants from AstraZeneca; has received travel and/or accommodation grants from Pfizer and Bristol-Myers Squibb. A. González-del-Alba has served as advisory role or consultant and has received travel grants and/or speaker honoraria from Pierre Fabre, Roche, Bristol-Myers Squibb, MSD, Pfizer, Novartis, Bayer, Janssen, Sanofi, Astellas, Ipsen, EUSA pharma and EISAI and has received research

funding from Astellas. E. Grande has received honoraria for advisory boards, meetings, and/or lectures from Pfizer, Bristol-Myers Squibb, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, and Celgene, and has received unrestricted research grants from Pfizer, AstraZeneca, MTEM/Threshold, Roche, IPSEN, and Lexicon. Cristina Suárez has served as advisory board to BMS, IPSEN, Novartis, Pfizer; has received travel grant to BMS; has served as speaker to AstraZeneca and Pfizer.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.